All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub was pleased to speak to Jeffrey Lancet, Moffit Cancer Center, Tampa, US. We asked, Are all-oral-based induction combinations the future for acute myeloid leukemia treatment?
Are all-oral-based induction combinations the future for AML treatment?
Lancet discusses the potential transition to all-oral-based induction regimens for the treatment of patients with acute myeloid leukemia, highlighting oral decitabine and cedazuridine plus venetoclax for older patients who are ineligible for intensive chemotherapy. He then highlights potential future novel combinations with oral targeted therapies, such as menin and isocitrate dehydrogenase inhibitors, and how they could expand the oral-based treatment options available to patients with targetable mutations. Lancet concludes by discussing potential challenges associated with all-oral-based regimens.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox